Coriolis Pharma

Advanced therapy medicinal products (ATMPs)

Formulation development and characterization of viral vectors & other ATMPs

ATMPs – including gene- and cell therapy medicinal products – offer new opportunities in addressing unmet medical needs and improving treatments for many diseases and injuries. Coriolis supports the development of ATMPs with a focus on formulation development and characterization of viral vectors, such as adeno-associated virus (AAV) and lentivirus vectors. Our services are also available for other drug products utilizing genetically modified organisms (GMOs) up to biosafety level (BSL) 2.

Our service portfolio under BSL2

Already at an early stage, Coriolis provides a tailored manufacturability / developability assessments of candidates utilizing our broad analytical portfolio. Our scientists also plan and conduct entire formulation development programs for your product, aiming to obtain stable liquid or lyophilized formulation. The latter includes a scientifically sound lyophilization process development from cycle optimization and robustness testing to scale-up and transfer. Stability and forced degradation studies support the formulation development efforts throughout all stages. In the final phase of development, Coriolis also offers in-use stability studies under BSL 2.